AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32890574
Drug: Ingestion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion group (CMF) - at least 10 mL of cow's milk formula daily between 1 and 2 months of age
Trial: 32890574
Drug: Avoidance group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoidance group (no CMF) - avoid cow's milk formula and supplement with soy formula as needed
Trial: 37798628
Drug: Custodiol cardioplegia
RxNorm normalized name: cardioplegia solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custodiol cardioplegia (CC)
Trial: 36484665
Drug: High-translucency zirconia
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-translucency zirconia with a partial buccal veneer (ZC-V)
Trial: 32457995
Drug: Ceftazidime administered
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime administered by continuous infusion
Trial: 32457995
Drug: Ceftazidime administered
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime administered by intermittent infusion
Trial: 35394149
Drug: Intramyocardial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramyocardial administration of autologous neonatal c-kit+ cardiac-derived progenitor cells (nCPCs)
Trial: 35394149
Drug: Randomized, double-blinded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, double-blinded administration of nCPCs
Trial: 34900170
Drug: Glucantime plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime plus SinaAmpholeish (topical nano-liposomal amphotericin B 0.4%)
Trial: 34900170
Drug: Glucantime (intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime (intralesional injections)
Trial: 33761143
Drug: 1.91 g
RxNorm normalized name: CAMPHOR (SYNTHETIC) 1.91 g in 100 g / MENTHOL 2.54 g in 100 g / METHYL SALICYLATE 1.62 g in 100 g TRANSDERMAL PLASTER [She Xiang Zhuang Gu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.91 g of red clover extract (containing 8 mg formononetin and 1.8 mg biochanin A)
Trial: 35995103
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g of tobacco)
Trial: 35995103
Drug: Normal Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg/g of tobacco)
Trial: 35172043
Drug: New tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet, fasted (reference, dosed twice)
Trial: 35172043
Drug: New tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet, 30 minutes after a high-fat meal (test 1)
Trial: 35172043
Drug: Old tablet,
RxNorm normalized name: Allergy/Cold Tablet, 12 mg-75 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old tablet, fasted (test 2)
Trial: 32912974
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy (MCT) plus usual care (UC)
Trial: 33649520
Drug: rostafuroxin 50
RxNorm normalized name: Rostafuroxin
DrugBank: Rostafuroxin (DB12350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rostafuroxin 50 μg
Trial: 35074878
Drug: High-cash gift
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cash gift group (monthly unconditional cash gift)
Trial: 35074878
Drug: Low-cash gift
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cash gift group (nominal monthly unconditional cash gift)
Trial: 35931480
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (PB) with 2 g of PBF1 added to colostrum and 1 g of PBF2 added to milk 3 times per week until weaning
Trial: 34003963
Drug: All subjects
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects (treatment agnostic)
Trial: 35832128
Drug: Continuous care
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous care based on the combination of medical care and nursing (Observation Group)
Trial: 34695679
Drug: Parent-administered early
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered early intervention
Trial: 35777616
Drug: Hybrid pegylated
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid pegylated liposomal doxorubicin (PLD) hydrochloride injection
Trial: 32003645
Drug: Ubiquinol-10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol-10 (300 mg/day)
Trial: 32988951
Drug: MyndMove neuromodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyndMove neuromodulation therapy
Trial: 32156479
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive drugs (Control)
Trial: 35881397
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with normal saline infusion (control)
Trial: 35241369
Drug: AC plus
RxNorm normalized name: Therevac Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC plus 0.5 µg of Vit D (Bon One 0.5 µg) orally once daily during the whole treatment course
Trial: 34761610
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) after surgery
Trial: 32649808
Drug: Sectional border
RxNorm normalized name: secobarbital sodium Oral Capsule [Seconal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sectional border molding technique using green stick compound (Z-group)
Trial: 34786906
Drug: Focused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Focused extracorporeal shock wave therapy (f-ESWT) on myofascial points
Trial: 34786906
Drug: Traditional focused
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional focused extracorporeal shock wave therapy (ESWT) on the medial calcaneal tubercle
Trial: 33009565
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (1.5% ammonium fluoride) applied every sixth week during orthodontic treatment
Trial: 33009565
Drug: Placebo varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo varnish (non-fluoride) applied every sixth week during orthodontic treatment
Trial: 36264751
Drug: Prophylactic negative-pressure
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic negative-pressure wound therapy (pNPWT) for 7 days
Trial: 36264751
Drug: Prophylactic negative-pressure
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic negative-pressure wound therapy (pNPWT)
Trial: 33825304
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 µg/g, group D)
Trial: 33825304
Drug: Midazolam (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.08 mg/kg, group M)
Trial: 33454739
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid antagonist
Trial: 32661106
Drug: Euglycemia, low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia, low insulin (EuLoI)
Trial: 32661106
Drug: Hyperglycemia, low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia, low insulin (HyLoI)
Trial: 32661106
Drug: Euglycemia, high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia, high insulin (EuHiI)
Trial: 34808255
Drug: Prophylactic gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic gabapentin (600 mg thrice daily)
Trial: 32822633
Drug: Atogepant 10
RxNorm normalized name: atogepant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 10 mg once daily
Trial: 32822633
Drug: Atogepant 30
RxNorm normalized name: atogepant 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 30 mg once daily
Trial: 38773375
Drug: Atogepant 60
RxNorm normalized name: atogepant 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 60 mg once daily
Trial: 32822633
Drug: Atogepant 30
RxNorm normalized name: atogepant 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 30 mg twice daily
Trial: 32822633
Drug: Atogepant 60
RxNorm normalized name: atogepant 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atogepant 60 mg twice daily
Trial: 36149220
Drug: Toothpaste with
RxNorm normalized name: SODIUM MONOFLUOROPHOSPHATE 1.1 g in 100 g DENTAL PASTE [Orbitol Fluoride Toothpaste with Baking Soda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste with sodium monofluorophosphate formulation
Trial: 34622845
Drug: A+HA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A+HA (20 mL supplement mixture containing 50 mg HA, 750 mg glucosamine, and 250 mg chondroitin)
Trial: 32673060
Drug: Hydroxychloroquine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days)
Trial: 34788698
Drug: Neoadjuvant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiation therapy
Trial: 34788698
Drug: Concurrent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy
Trial: 32188492
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus 1g of intravenous calcium gluconate (group 2)
Trial: 32188492
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (morphine 0.1 mg/kg + normal saline; group 1)
Trial: 33272766
Drug: Waitlist-control (treatment-as-usual)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist-control (treatment-as-usual)
Trial: 32901283
Drug: Rotta glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotta glucosamine (DONA powder sachets, 1500 mg/day)
Trial: 32901283
Drug: Non-Rotta glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Rotta glucosamine (glucosamine sulphate 1500 mg one-a-day tablet)
Trial: 32463382
Drug: Inhalation aromatherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation aromatherapy with lavender and sweet orange
Trial: 32390170
Drug: Guided tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided tissue regeneration (GTR) therapy
Trial: 35533791
Drug: Short-course IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course IV antibiotics (2 weeks)
Trial: 35533791
Drug: Standard-course IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-course IV antibiotics (6 weeks)
Trial: 35109491
Drug: Small group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small group music therapy (GMT)
Trial: 32363616
Drug: Synbiotic supplementation
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplementation (500 mg/day)
Trial: 33931405
Drug: Immune therapy
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune therapy
Trial: 32067293
Drug: Mindful Yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Yoga Intervention (MYI) added to Treatment as Usual (TAU)
Trial: 34915084
Drug: Neurofilament light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofilament light chain dosage (NF‐L) at thresholds of 500 pg/ml and 1,200 pg/ml added to the modified ESICM/ERC 2021 algorithm.
Trial: 34915084
Drug: Unmodified ESICM/ERC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified ESICM/ERC 2021 algorithm without NF‐L.
Trial: 34915084
Drug: Neurofilament light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofilament light chain (NF‐L) values for good versus poor outcomes.
Trial: 32846798
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) administration [1 g] before skin incision
Trial: 34002563
Drug: Gel plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel plaster
Trial: 39112892
Drug: Enriched Music-supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched Music-supported Therapy (eMST)
Trial: 34979513
Drug: Levetiracetam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (250 mg to a maximum of 1,500 mg)
Trial: 34979513
Drug: Levetiracetam (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (250 mg to a maximum of 1,500 mg) and Placebo
Trial: 32311006
Drug: Chronic physical
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic physical illness and functions of daily living
Trial: 32097392
Drug: Argon plasma
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon plasma coagulation (APC) treatment offered in 96% of cases
Trial: 33852730
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (TMI) in addition to group counseling, nicotine patches, and written material; Duration: 6 weeks
Trial: 33852730
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (group counseling, nicotine patches, and written material)
Trial: 34903344
Drug: Drug-eluting stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting stents (DES) used in 76% of BVS-ISR patients
Trial: 34098214
Drug: High-protein group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein group (HPG) - 25% daily calorie of protein
Trial: 34098214
Drug: Regular-protein group
RxNorm normalized name: PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-protein group (RPG) - 15% daily calorie of protein
Trial: 34134881
Drug: Extended-release injectable
RxNorm normalized name: Exenatide for Extended-Release Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release injectable naltrexone before release (BR)
Trial: 34134881
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to treatment after release (AR)
Trial: 32345253
Drug: SMAQ (Simplified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMAQ (Simplified Medication Adherence Questionnaire) at T1 (baseline)
Trial: 32345253
Drug: SMAQ (Simplified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMAQ (Simplified Medication Adherence Questionnaire) at T2 (follow-up)
Trial: 32147082
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment plus conventional treatment
Trial: 33957854
Drug: Influvac® Tetra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influvac® Tetra (subunit, inactivated influenza vaccine)
Trial: 33957854
Drug: VaxiFlu‐4 (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VaxiFlu‐4 (split virion, inactivated influenza vaccine)
Trial: 35973226
Drug: Novel antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel antimicrobial wound gel system
Trial: 35353636
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using gallium aluminum arsenide (GaAlAs) laser with parameters: wavelength of 810 nm, power of 0.5% ± 20% W, energy density of 4 J/cm2.
Trial: 35353636
Drug: Ibuprofen (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (control group).
Trial: 33351989
Drug: 1.0% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% chlorhexidine gluconate solution preoperatively
Trial: 35737699
Drug: Laser-based cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-based cavity preparation with acid etching (test group I, n = 21)
Trial: 35737699
Drug: Laser-based cavity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-based cavity preparation without acid etching (test group II, n = 21)
Trial: 35737699
Drug: Conventional diamond
RxNorm normalized name: diamond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diamond burs preparation (control group, n = 33)
Trial: 33453391
Drug: Niraparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (300 mg/day or 200 mg/day based on body weight and platelet count)
Trial: 33610422
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg resveratrol daily for 3 months
Trial: 33610422
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg placebo daily for 3 months
Trial: 36045021
Drug: CD20-targeting agents
RxNorm normalized name: HuMax-CD20
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CD20-targeting agents
Trial: 36045021
Drug: No CD20-targeting
RxNorm normalized name: NO
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No CD20-targeting agents
Trial: 35258443
Drug: Meropenem 2
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2 g every 8 hours (TID)
Trial: 35258443
Drug: Meropenem 2
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2 g TID plus rifampin at 20 mg/kg once daily
Trial: 35258443
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g TID
Trial: 35258443
Drug: Meropenem 3
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 3 g once daily
Trial: 32860696
Drug: High frequency
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High frequency chest wall oscillation and conventional chest physical therapy (breathing exercises, early ambulation, and cough training) thrice per week for 8 weeks
Trial: 32860696
Drug: Traditional chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional chest physical therapy (breathing exercises, early ambulation, and cough training) thrice per week for 8 weeks
Trial: 34237210
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A)
Trial: 35246214
Drug: Opioid-sparing therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-sparing therapies
Trial: 35246214
Drug: Opioid-based therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-based therapies
Trial: 32068667
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration desipramine titrated to reach a serum concentration level of 15 to 65 ng/mL
Trial: 32068667
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and active placebo medication (benztropine mesylate, 0.125 mg)
Trial: 32068667
Drug: Active benztropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active benztropine placebo medication
Trial: 33734127
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac sodium (1.5 mg/kg)
Trial: 32212810
Drug: 30 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 cisplatin weekly (Arm A)
Trial: 32212810
Drug: 100 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 cisplatin once every 3 weeks (Arm B)
Trial: 35720170
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) 115 ml daily for 7 days
Trial: 35720170
Drug: Green leafy
RxNorm normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green leafy vegetable juice 250 ml daily for 7 days
Trial: 36377523
Drug: Vortioxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine treatment
Trial: 32044511
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) using anthracycline-based regimen without taxanes